+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Pancreatic Cancer Therapeutics and Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

  • PDF Icon


  • 204 Pages
  • August 2022
  • Region: Global
  • Mordor Intelligence
  • ID: 4591754
UP TO OFF until Sep 30th 2023
The global pancreatic cancer therapeutics and diagnostics market is estimated to be USD 3,689.61 million in 2021 and is expected to reach USD 5,656.58 million by 2027, registering a CAGR of 7.43% from 2022 to 2027.

The outbreak of COVID-19 significantly reduced hospital and healthcare services, impacting the pancreatic cancer therapeutics and diagnostics market. Moreover, the COVID-19 pandemic affected the global economy and showed a huge impact on the functioning of general hospital care for non-COVID-19 patients in hospitals. In June 2020, an article appearing in the National Center for Biotechnology Information studied the impact of the COVID-19 pandemic on the use of endoscopy units globally. The study looked into 55 countries across 6 continents from April 23 to May 12, 2020. The study found that the number of endoscopy procedures performed during the COVID-19 pandemic decreased, constituting an 83% reduction compared to the baseline figures. The study also found out that there was an 82% reduction in upper endoscopy procedures and an 85% reduction in lower endoscopy procedures during the same time. In August 2020, a survey was published in PubMed on the impact of COVID-19 on pancreatic surgery for cancer patients. The survey was conducted amongst 337 respondents from 267 centers from 37 countries. According to the survey, most centers performed fewer pancreatic surgeries due to the COVID-19 pandemic, which reduced the weekly pancreatic resection rate from 3 to 1. Thus, the COVID-19 pandemic is expected to impact the studied market's growth significantly.

Pancreatic cancer therapeutics and diagnostics involve medical procedures used to diagnose pancreatic cancer and subsequent treatment. Factors such as the increasing prevalence and incidence of pancreatic cancer and advancements in molecular biology, development of drugs, and diagnostic technology play a major part in market growth. With the increase in R&D initiatives, favorable reimbursement scenarios, and the launch of novel products, the market is expected to grow significantly during the forecast period. In January 2019, scientists from the Van Andel Research Institute (VARI) developed a novel blood test (CA19-9 test) that, when combined with an existing test, can detect nearly 70% of pancreatic cancers with a less than 5% of false-positive rate. Moreover, in January 2021, Myriad Genetics Inc. announced that it would receive reimbursement for its BRACAnalysis Diagnostic System, which is also used for pancreatic cancer screening from Japan's Ministry of Health, Labour, and Welfare. The initiative is expected to increase the patient pool for genetic testing for pancreatic cancer in Japan. Also, many collaborations are taking place in the market, which is expected to affect market development positively. In October 2020, Oncolytics Biotech Inc. announced a collaboration with Roche and AIO for a phase 1/2 trial of testing the efficacy of pelareorep and atezolizumab in the treatment of metastatic pancreatic cancer. Thus, these developments are expected to impact the studied market growth over the forecast period positively.

Key Market Trends

The Chemotherapy Segment is Expected to Witness a Major Share in the Studied Market Over the Forecast Period

Chemotherapy is one of the main cancer treatments that kill pancreatic cancer cells by preventing them from growing and dividing. These drugs are systemic treatments; the drugs travel through the bloodstream and damage cancer cells throughout the body. Unfortunately, chemotherapy can damage some healthy cells and cause major side effects. Chemotherapy may shrink and/or prevent the growth of pancreatic tumors. According to the American Cancer Society, the chemotherapy drugs used to treat pancreatic cancer include Gemcitabine (Gemzar), 5-fluorouracil (5-FU), Irinotecan (Camptosar), Oxaliplatin (Eloxatin), Albumin-bound paclitaxel (Abraxane), Capecitabine (Xeloda), Cisplatin, Paclitaxel (Taxol), Docetaxel (Taxotere), and Irinotecan liposome (Onivyde).

Since the 1990s, the chemotherapy drug gemcitabine (Gemzar) has been the backbone of treating people with pancreatic cancer that can be removed with surgery (resectable). Traditionally, gemcitabine has been given as adjuvant chemotherapy after the patient has recovered from the surgery, which, for many patients, is a grueling procedure known as the Whipple procedure. More recently, gemcitabine is sometimes combined with the chemotherapy drug capecitabine (Xeloda). Chemotherapy may also be given alone or combined with surgery, targeted therapy, immunotherapy, and/or radiation. When chemotherapy is given in combination with radiation, a low dose of chemotherapy is typically used. The chemotherapy drugs most commonly used in conjunction with radiation therapy are fluorouracil (5-FU) and gemcitabine (Gemzar). 5-FU is used most often since there is more experience using this drug in combination with radiation, and there are fewer side effects.

In March 2020, the Pancreatic Cancer Collective, the strategic partnership of the Lustgarten Foundation and Stand Up To Cancer (SU2C), was awarded up to USD 16 million to four teams of top researchers, including a team at Dana-Farber Cancer Institute, as part of its New Therapies Challenge Grants, the American Association for Cancer Research (AACR), and Scientific Partner of SU2C. Nearly USD 4 million in funding is available to help support three pancreatic cancer clinical trials testing DNA repair inhibitors combined with chemotherapy. Thus, due to the surging demand for effective treatment options for pancreatic cancers, the studied segment is expected to witness significant growth over the forecast period.

North America Dominated the Overall Market and is Expected to Retain its Dominance

The United States is expected to retain its significant market share due to the rising incidence of pancreatic cancers, supportive reimbursement policies, and high healthcare spending.

As per a 2018 publication in the MedCrave Gastroenterology and Hepatology journal, pancreatic cancer was the ninth most frequent cancer, despite its moderate incidence. It was expected to be among the second-deadliest cause of cancer by 2030. Also, according to the GLOBOCAN 2020 report, about 56,654 new cases of pancreatic cancer were reported in 2020. Moreover, approximately 47,683 deaths due to pancreatic cancer were reported in the United States. The USFDA is also taking steps to enhance the growth of the pancreatic cancer therapeutics and diagnostic market by approving drugs in the clinical phase, thereby accelerating clinical developments. Companies and research organizations are investing in R&D. Thus, the market is expanding quickly. For instance, in 2020, ERYTECH's lead product candidate, eryaspase, received the fast track designation by the FDA due to the urgent need for potential new treatment options for patients with second-line metastatic pancreatic cancer in the country. Such product approvals by the FDA are expected to lift the overall market.

In 2020, NANOBIOTIX announced its first phase I trial with NBTXR3 in Pancreatic Cancer, which is safe to proceed as per the US FDA. The trial was co-developed with Nanobiotix, and MD Anderson is the sponsor and executor of the trial. These clinical trials' positive outcomes will result in a new treatment, positively influencing the regional market growth. Thus, owing to the factors mentioned above, the studied market is anticipated to register significant growth over the forecast period in the region.

Competitive Landscape

The Pancreatic Cancer Therapeutics and Diagnostics market is highly competitive, with many key players dominating the market. The presence of major market players like Novartis AG, Pfizer Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Myriad Genetics Inc., and Viatris Inc. is intensifying the competition. The market players are adopting strategies, such as rising R&D investments, mergers, acquisitions, and product innovations, to sustain the increasing market rivalry. For instance, in January 2021, Myriad Genetics Inc. entered into a strategic partnership with Illumina Inc. for the latter to create a kit-based version of the myChoice companion diagnostic (CDx) test for international markets, which can be used to detect pancreatic cancer.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidence and Prevalence of Pancreatic Cancer
4.2.2 Advancements in Molecular Biology, Development of Drugs, and Diagnostic Technology
4.3 Market Restraints
4.3.1 High Costs Associated with Diagnosis and Treatments
4.3.2 Stringent Regularity Guidelines
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Type
5.1.1 By Treatment Targeted Therapies Chemotherapy Surgery Other Treatments
5.1.2 By Diagnostics Imaging Biopsy Endoscopic Ultrasound Other Diagnostics
5.2 Geography
5.2.1 North America United States Canada Mexico
5.2.2 Europe United Kingdom Germany France Italy Spain Rest of Europe
5.2.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.2.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.2.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 Myriad Genetics Inc.
6.1.2 Pfizer Inc.
6.1.3 Novartis AG
6.1.4 Bristol-Myers Squibb Company
6.1.5 AstraZeneca PLC
6.1.6 Amgen Inc.
6.1.7 Viatris Inc.
6.1.8 Boston Scientific Corporation
6.1.9 FUJIFILM Holdings Corporation
6.1.10 Canon Inc. (canon Medical Systems Corporation)
6.1.11 Rafael Holdings Inc (rafael Pharmaceuticals)
6.1.12 Immunovia AB
6.1.13 Apexigen Inc.
6.1.14 Merck KGaA
6.1.15 F Hoffmann-La Roche AG

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Myriad Genetics Inc.
  • Pfizer Inc.
  • Novartis AG
  • Bristol-Myers Squibb Company
  • AstraZeneca PLC
  • Amgen Inc.
  • Viatris Inc.
  • Boston Scientific Corporation
  • FUJIFILM Holdings Corporation
  • Canon Inc. (canon Medical Systems Corporation)
  • Rafael Holdings Inc (rafael Pharmaceuticals)
  • Immunovia AB
  • Apexigen Inc.
  • Merck KGaA
  • F Hoffmann-La Roche AG